Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Suletud

SektorTervishoid

8.86 10.06

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.5

Max

8.91

Põhinäitajad
By Trading Economics
Sissetulek	-16M -3.8M
Müük	-31M 45M
P/E Sektori keskmine	16.521 68.51
Aktsiakasum	-0.04
Kasumimarginaal	-8.375
Töötajad	179
EBITDA	-27M -196K

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-32.66% downside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. nov 2026

Turustatistika
By TradingEconomics
Turukapital	20M 404M
Eelmine avamishind	-1.2
Eelmine sulgemishind	8.86

Uudiste sentiment

By Acuity

26%

74%

50 / 340 Pingereas Healthcare

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. aug 2026, 20:02 UTC

News

Puma Biotechnology shares rise following strong earnings and TD Cowen's price target increase to $6.00. Trading volume indicates heightened investor interest.

6. aug 2026, 19:26 UTC

Puma Biotechnology Inc shares are higher Thursday, maintaining upward momentum after three consecutive gains, despite a pullback earlier in the session.

5. aug 2026, 21:51 UTC

News

Puma Biotechnology shares are trading lower in after-market hours following the grant of stock awards to new employees, which may dilute existing shareholder value.

4. aug 2026, 19:56 UTC

Puma Biotechnology Inc is trading higher today, benefiting from a decline in crude oil prices that eased inflation concerns. Shares earlier pulled back from a session high.

3. aug 2026, 19:51 UTC

Puma Biotechnology Inc shares are lower today, reflecting a decline since Friday. The stock saw significant volatility, initially rising before dropping sharply.

31. juuli 2026, 19:16 UTC

Puma Biotechnology Inc shares are lower today, continuing a decline since Thursday's close. The stock is trading near the lower end of its one-month range.

30. juuli 2026, 18:31 UTC

Puma Biotechnology Inc shares are higher as the overall market recovers from recent declines. The stock remains below its 20-day moving average.

29. juuli 2026, 18:23 UTC

Puma Biotechnology Inc shares are lower amid broader market weakness as investors await the Federal Reserve's interest rate decision this afternoon.

28. juuli 2026, 18:06 UTC

Puma Biotechnology shares are lower amid broader market trends, influenced by declines in Asian markets, particularly in technology sectors.

27. juuli 2026, 19:46 UTC

Puma Biotechnology Inc shares are higher, reflecting broader market gains amid a significant decline in crude oil prices following geopolitical developments.

24. juuli 2026, 19:26 UTC

Puma Biotechnology Inc. shares are roughly flat as no specific news emerged during Friday's trading session, fluctuating within a routine range.

23. juuli 2026, 20:06 UTC

Puma Biotechnology Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday's close amid no specific news identified.

22. juuli 2026, 22:51 UTC

Puma Biotechnology Inc shares are trading higher in after-market hours, building on earlier gains. The stock remains above its 20-day moving average.

21. juuli 2026, 18:02 UTC

Puma Biotechnology Inc shares are higher during Tuesday's session, continuing a positive trend since Monday. The stock remains above its 20-day moving average.

20. juuli 2026, 20:06 UTC

Puma Biotechnology Inc shares are lower today, having reached a mid-day low of -4.46%. No specific news has been identified to explain the decline.

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-32.66% langus

12 kuu keskmine prognoos

Keskmine 6 USD -32.66%

Kõrge 6 USD

Madal 6 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

50 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.